Assessment of malignancy in adrenal cortical tumors.
The roles of the pathologist in assessing adrenal cortical tumors are, first, to differentiate adenoma from carcinoma, and, second, to assess prognosis when the diagnosis of malignancy is made. How easy is it to achieve these goals with standard histology and immunohistochemistry, and to what extent can molecular analysis help?
McNicol
Anne Marie
AM
Division of Cancer Sciences and Molecular Pathology, University of Glasgow, Pathology Department, Royal Infirmary, Castle Street, Glasgow G4 0SF, UK.
D000236:Adenoma / Q000235:genetics / Q000473:pathology*; D000306:Adrenal Cortex Neoplasms / Q000235:genetics / Q000473:pathology*; D014408:Biomarkers, Tumor / Q000032:analysis; D002277:Carcinoma / Q000235:genetics / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D008967:Molecular Biology; D009361:Neoplasm Invasiveness / Q000175:diagnosis* / Q000235:genetics; D011379:Prognosis
D014408:Biomarkers, Tumor